1.866.771.8946

LinkedIn Google+ Twitter Facebook

Carisome® Microvesicle Technology

Engineered by Caris Life Sciences®, Carisome Technology represents an opportunity to transform healthcare through blood-based diagnostics, prognostics, and therapeutic guidance to aid clinicians and their patients with treatment decisions. Caris is pioneering major advances in the understanding of blood-based circulating microvesicles (cMV) and their application to patient care, through more accurate diagnosis and therapeutic planning.

Using a novel, proprietary, patent-pending platform, Caris is able to rapidly and accurately identify and characterize disease-associated circulating microvesicles from the blood. This unique and promising technology has the potential for direct clinical utility in early diagnostic testing, disease monitoring, and therapeutic response in cancer patients.

Caris Presents


Caris Life Sciences Molecular Oncology Services

Caris' scientific experts contribute to the advancement of science at various symposia and conferences worldwide.

learn more

“WE INTEND TO HELP RELIEVE THE SUFFERING OF AS MANY PEOPLE AS POSSIBLE”


David D. Halbert Chairman & CEO